PC25050A
Information Disclosure Statement For Appln. No. 10/699,068

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 7th day of January 2004.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
QIYUE HU, et al.

Serial No.: 10/699,068

Confirmation No.: Not yet assigend

Filed: October 30, 2003

For: HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)--i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: 7 January 2004

Jeffrey W. Rennecker
Attorney For Applicant
Registration No. 40,784

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-8807
Fax: (858) 678-8233

PTO.SB/08A (04-03)
Approved for use through 04/30/03. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. Department of Commerce

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No.[1]	DOCUMENT NUMBER Number-Kind Code[2]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	60/422,513	10-31-2002	Michael Bruno Plewe, et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AB	WO 02/070491	12/09/2003	Shionogi & Co., Ltd.		

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO.SB/08A (04-03)
Approved for use through 04/30/03. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. Department of Commerce

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AC	ABDEL-MAGID, A.F., et al., "Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride," *Tetrahedron Letters*, 1990, 5595-5598, Vol. 31, No. 39.	
	AD	ABDEL-MAGID, et al., "Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride," *Journal of Organic Chemistry*, 1996, 3849-3862, Vol. 61.	
	AE	BAGSHAWE, K., "Antibody-Directed Enzyme Prodrug Therapy: A Review," *Drug Development Research*, 1995, 220-230, Vol. 34.	
	AF	BERTOLINI, et al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immonsuppresive Drug," *Journal of Medicinal Chemistry*, 1997, 2011-2016, Vol. 40.	
	AG	BIERE, H., et al., "Ein einfacher Zugang zum Pyrrolo[1,2-*c*]pyrimidin und Pyrrolo[3,2-*c*]pyridin-System," *Liebigs Ann. Chem.*, 1987, 491-497.	
	AH	BLATT, A. H., et al., Organic. Synthesis, Collective Volume 2., 1943, 67, Vol. 2, John Wiley & Sons, New York.	
	AI	BODOR, "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," *Advances in Drug Research*, 1984, 255-331, Vol. 13.	
	AJ	BREWSTER, J., et al., "Carbon-Carbon Alkylations with Amines and Ammonium Salts," Organic Reactions, Vol. VII, 1953, 99-197, Vol. 7.	
	AK	BUNDGAARD, Design of Prodrugs, 1985, Elsevier Press, New York.	
	AL	BUTLER, S.L., et al., "A quantitative assay for HIV DNA integration *in vivo*," *Nature Medicine*, May 2001, 631-634, Vol. 7, No 5.	
	AM	CAIN, M., et al., "Biomimetic Approach to Potential Benzodiazepine Agonists and Antagonists," *Heterocycles*, 1982, 1003-1007, Vol. 19, No. 6.	
	AN	CHEN, B.K., et al., "Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses," *Journal of Virology*, 1994, 654-660, Vol. 68, No. 2.	
	AO	CHEN, et al., "Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding," *PNAS*, 2000, 8233-8238, Vol. 97, No. 15.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

	AP	COKER, J.N., et al., "The Cyanomethylation of Indole," *Journal of Organic Chemistry*, 1963, 589-590, Vol. 28.	
	AQ	DEAR, et al., "Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography – mass spectrometry – nuclear magnetic resonance spectroscopy," *Journal of Chromatography B,* 2000, 281-293. Vol. 748.	
	AR	DEBYSER, Z., et al., "Assays for the Evaluation of HIV-1 Integrase Inhibitors," Methods in Molecular Biology, 2001, 139-155, Vol. 160, Schein, C.H. (ed.), Humana Press, Inc., Totawa, NJ.	
	AS	DEKHANE, M., et al., "A Practical Synthesis of 1h-Pyroolo[2,3-c]Pyridine-5-Carboxylic Acid Derivatives From Pyrrole-2-Carboxaldehydes," *Tetrahedron*, 1993, 8139-8146, Vol. 49, No. 36.	
	AT	DODD, R.H., et al., "The Oxidation of Aromatic Aldehydes to Carboxylic Acids Using Hydrogen Peroxide in Formic Acid," *Synthesis*, 1993, 295-297.	
	AU	DODD, R.H., et al., "Synthesis and Pharmacological Activity of a Pyrido [3',4':5,4]Pyrrolo[1,2-c]-c[1,4] Benzodiazepine-3, 10-Dione, A New Benzodiazepine-ß-Carboline Type Hybrid Molecule," *Heterocycles*, 1989, 1101-1113, Vol. 28, No. 2.	
	AV	DOISY, X., et al., "Synthesis and Benzodiazepine Receptor (ω Receptor) Affinities of 3-Substituted Derivatives of Pyrrolo[2,3-c]pyridine-5-Carboxylate, a Novel Class of ω_1 Selective Ligands," *Bioorganic Medicinal Chemistry*, 1999, 921-932, Vol. 7.	
	AW	EBERLE, M.K., "Contribution to the Chemistry of Indole About the 5-(1-Indolyl)-2-pentanone System," *Journal of Organic Chemistry*, 1976, 633-636, Vol. 41, No. 4.	
	AX	GILCHRIST, T.L., et al., "Synthesis of Fused Pyridines under Neutral Conditions," *J.C.S. Chem. Comm.*, 1979, 627-628.	
	AY	GOLDGUR, Y., et al., "Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design," PNAS, November 1999, 13040-13043, Vol. 96, No. 23.	
	AZ	GREENE, T.W., Protective Groups in Organic Chemistry,"3rd Edition, 1999, 531-537, John Wiley & Sons.	
	BA	GROBLER, J., et al., "Diketo Acid Inhibitor Mechanism and HIV-1 Integrase: Implications for Metal Binding in the Active Site of Phosphotransferase Enzymes," *PNAS*, 2002, 6661-6666, Vol. 99, No. 10.	
	BB	GUZMAN, F., et al., "Biomimetic Approach to Potential Benzodiazepine Receptor Agonists and Antagonists," *Journal of Medicinal Chemistry*, 1984, 564-570, Vol. 27.	
	BC	HANSEN, M. S., et al., "Integration complexes derived from HIV vectors for rapid assays in vitro," *Nature Biotechnology*, June 1999, 578-582, Vol. 17, No. 6.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

	BD	HAZUDA, D., et al., "Discovery and Analysis of Inhibitors of the Human Immunodeficiency Integrase," *Drug Design and Discovery*, 1997, 17-24, Vol. 15.	
	BE	HENN, L., et al., "Formation of Indoles, Isoquinolines, and Other Fused Pyridines from Azidocrylates," *J. Chem. Soc. Perkin Trans.*, 1984, 2189-2196, Vol. 1.	
	BF	HUGHES, D., "Progress in the Mitsunobu Reaction. A Review," *Org. Prep. Proced. Int.*, 1996, 127-164, Vol. 28.	
	BG	JENKINS, T.M., et al., "A Soluble Active Mutant of HIV-1 Integrase," *Journal of Biological Chemistry*, 1996, 7712-7718, Vol. 271, Vol. 13.	
	BH	KANTLEHNER, W., et al., "Umsetzungen von *tert*-Butoxy-*N,N,N',N'*-tetramethylmethandiamin mit NH- und CH-aciden Verbingdungen," *Liebigs Ann. Chem.*, 1980, 344-357.	
	BI	KELLEY, J.L., et al., "Attempted Inhibition of Histidine Decarboxylase with β-Alkyl Analogues of Histidine," *Journal of Medicinal Chemistry*, 1977, 721-723, Vol. 20, No. 5.	
	BJ	KOZIKOWSKI, A. P., et al., "Use of N,N-Dimethyl(Methylene)Ammonium Chloride in the Functionalization of Indoles," *Heterocycles*, 1980, 55-58, Vol. 14, No. 1.	
	BK	KREHER, R. P., et al., "Cyclisierende Kondesation von 1H_Pyrrol-3,4-dicarbaldeyden mit 1,2-bifunktionellen Verbindugen [1]," *Chemiker-Zeitung*, 1984, 275-277, Vol. 108, No. 9.	
	BL	KRUTOSIKOVA, A., et al., "Condensed O-, N-Heterocycles by the Transformation of Azidoacrylates," *Monatsh. Chem.*, 1992, 807-815, Vol. 123.	
	BM	LANE, C. F., "Sodium Cynanoborohydride – A Highly Selective Reducing Agent for Organic Functional Groups," *Synthesis*, 1975, 135-146.	
	BN	LARSEN, "Design and Application of Prodrugs." *Drug Design and Development*, 1991, Krogsgaard-Larsen et al., Eds., Harwood Academic Publishers, Chur, Switzerland.	
	BO	LEE, J.G., et al.,"Aromatization of Cyclohexenes and Cyclohexadienes With Selenium Dioxide-Trimethylsilyl Polyphosphate," *Tetrahedron Letters*, 1992, 6363-6366, Vol. 33, No. 42.	
	BP	LEWIN, S.R., et al., "Use of Real-Time PCR and Molecular Beacons to Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy," *Journal of Virology*, July 1999, 6099-6103, Vol. 73, No 7.	
	BQ	MARCH, JERRY, Advanced Organic Chemistry, 5TH Edition, 2001, 508-511, John Wiley & Sons, Inc., New York, NY.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

	BR	MARCH, JERRY, Advanced Organic Chemistry, 5TH Edition, 2001, 911-914, John Wiley & Sons, New York, NY.	
	BS	MATAKA, S., et al., "Condensation Reaction of 3,4-Dibenzoyl-1-methyl-2,5-diphenylpyrrole and –1-phenylpyrazole with Methylamine Derivatives Affording Pyrrolo [3,4-*c*]pyridine and 2*H*-Pyrazolo[3,4-*c*]- and [4,3-*c*]pyridines," *J. Heterocyclic. Chem.*, 1981, 1073-1075, Vol. 18.	
	BT	MOLINA, P., et al., "An Efficient Iminophosphorane-Mediated Synthesis of Thieno[3,2-c]pyridine, Thieno[2,3-c]pyridine and Furo[3,2-c]-pyridine Derivatives," *Synthesis*, 1987, 45-48.	
	BU	MOLINA, P., et al., "Pyrido Annelation Reaction by a Tandem Aza Wittig/Electro-cyclic Ring-Closure Strategy: Preparation of Pyrazolo [4,3-c]- and Pyrazolo[3,4-c]pyridine Derivatives," *Tetrahedron*, 1991, 6737-6746, Vol. 47, No. 33.	
	BV	PAIS, G.C.G., et al., "Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors," *Journal of Medicinal Chemistry*, 2002, 3184-3194, Vol. 45.	
	BW	PROX, et al., "Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes," *Xenobiotica.*, 1973, 103-112, Vol. 3, No. 2.	
	BX	ROUSSEAU, J.F., et al., "Synthesis and Pharmacological Activity of a Pyrido[3',4':5,4]Pyrrolo[1,2-c]-[1,4]Benzodiazepine-3,10-Dione, A New Benzodiazepine-β-Carboline Type Hybrid Molecule," *Heterocycles*, 1989, 1101-1113, Vol. 28.	
	BY	ROUSSEAU, J.F., et al., "Synthesis of 3-Deaza-β-hydroxyhistidine Derivatives and Their Use for the Preparation of Substituted Pyrrolo[2,3-c]pyridine-5-carboxylates via the Pictet-Spengler Reaction," *Journal of Organic Chemistry*, 1998, 2731-2737, Vol. 63.	
	BZ	SAYASITH, K., et al., "Targeting HIV-1 Integrase," *Expert Opinion Ther. Targets*, 2001, 443-464, Vol. 5, No.4.	
	CA	SHAFIEE, A., et al., "Synthesis of 2-Aryl-6-carbethoxythiazolo[4,5-c]pyridine and 7-Chloro-2-phenylthiazolo[5,4-c]pyridine [1]," *J. Heterocyclic Chem.*, 1986, 1171-1173, Vol. 23.	
	CB	SHAN, D., et al., "Prodrug Strategies Based on Intramolecular Cyclization Reactions," *Journal of Pharmaceutical Science*, 1997, 765-767, Vol. 86, No. 7.	
	CC	SINGH, S.K., et al., "Ethyl α-Amino-β,β-Diethoxypropionate, a Useful Synthon for the Preparation of 3,4-Fused Pyridine-6-Carboxylates from Aromatic Aldehydes," *Heterocycles*, 1997, 379-391, Vol. 44, No. 1.	
	CD	SOERENS, D., et al., "Study of the Pictet-Spengler Reaction in Aprotic Media: Synthesis of the β-Galactosidase Inhibitor, Pyridindolol," *Journal of. Organic Chem*istry, 1979, 535-545, Vol. 44, No. 4.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/699,068
Filing Date	October 30, 2003
First Named Inventor	Qiyue Hu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25050A

	CE	SPRAUL, et al., "Liquid chromatography coupled with high-field proton NMR for profiling human urine for endogenous compounds and drug metabolites," *Journal of Pharmaceutical & Biomedical Analysis*, 1992, 601-605, Vol. 10, No. 8.	
	CF	STILL, et al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution," *Journal of Organic Chemistry*, 1978, 2923-2925, Vol. 43, No. 14.	
	CG	SUNDBERG, R.J., et al., "Syntheses with N-Protected 2-Lithioindoles," *Journal of Organic Chemistry*, 1973, 3324-3330, Vol. 38, No. 19.	
	CH	TERWILLIGER, E.F., et al., "Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetryltransferase enzyme," *PNAS*, 1989, 3857-3861, Vol. 86.	
	CI	TROUT, G., et al., "Synthesis of Some Histidine Analogs and Their Effect on the Growth of a Histidine-Requiring Mutant of *Leuconostoc mesenteroides*," *Journal of Medicinal Chemistry*, 1972, 1259-1261, Vol. 15, No. 12.	
	CJ	WAI, J.S., et al., "4-Aryl-2,4-dioxobutanoic Acid Inhibitors of HIV-1 Integrase and Viral Replication in Cells," *Journal of Medicinal Chemistry*, 2000, 4923-4926, Vol. 43, No 26.	
	CK	WEISLOW, O.S., et al., "New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity," *J. Natl. Cancer Inst.*, 1989, 577-586, Vol. 81, No. 8.	
	CL	YOUNG, S.D., "Inhibition of HIV-1 integrase by small molecules: The potential for a new class of AIDS chemotherapeutics," *Curr. Opin. Drug Disc. & Develo*pment, 2001, 402-410, Vol. 4 No.4.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.